About Us
Company Overview
Leadership Team
Board of Directors
Scientific Advisory Board
Contact Us
Our Approach
The Opportunity in China
The Everest Advantage
Partners
Pipeline
Media
Investors
News
Search
14
2022/01
Everest Medicines Enters into a Global Licensing Agreement to Develop and Commercialize Singapore’s Experimental Drug Development Centre’s 3CL Protease Inhibitors as Potentially Best-in-Class COVID-19 Oral Antiviral Treatments Worldwide
10
2022/01
Everest Medicines Will Participate in a Clinical Trial with Gilead and MSD to Evaluate Trodelvy
®
in Combination with KEYTRUDA
®
(pembrolizumab) in First-Line Metastatic Non-Small Cell Lung Cancer
04
2022/01
Everest Medicines Announces Taiwan FDA Has Accepted New Drug Application for Sacituzumab Govitecan in Second-Line Metastatic Triple-Negative Breast Cancer
20
2021/12
Everest Medicines and Providence Therapeutics announces that PTX-COVID19-B, a mRNA Vaccine for COVID-19, has received approval for inclusion in WHO Solidarity Trial Vaccines (STV) Program
16
2021/12
Everest Medicines announces FDA grants our Partner Calliditas Therapeutics Accelerated Approval of TARPEYO™ (budesonide) to Reduce Proteinuria in IgA Nephropathy
15
2021/12
Everest Medicines Announces the Acceptance of a New Drug Application for Sacituzumab Govitecan in Second-Line Metastatic Triple-Negative Breast Cancer in South Korea
01
2021/12
Everest Medicines and Providence Therapeutics Jointly Announce Vaccine Development Strategy to Address Omicron (B.1.1.529) SARS-CoV-2 Variant
24
2021/11
Everest Medicines Announces Inclusion in the MSCI Global Small Cap Indexes - MSCI China Index
11
2021/11
Everest Medicines and Gilead Sciences Jointly Announce Phase 2b Study of Sacituzumab Govitecan Conducted in China of Patients with Metastatic Triple-Negative Breast Cancer Meets Primary Overall Response Rate Endpoint
08
2021/11
Everest Medicines Announces Up to HK$100 million Additional Share Repurchase Program
01
2021/11
Everest Medicines Announces Share Repurchase Transaction Details
29
2021/09
Everest Medicines Initiates Submission of New Drug Application in Hong Kong for Xerava
TM
for the Treatment of Complicated Intra-abdominal Infections
<<
<
1
2
3
4
5
6
7
8
>
>>
Copyright Everest Medicines 2020 云顶药业(苏州)有限公司
苏ICP备20038571号
|
Terms of Use
|
Privacy Policy
|
Disclaimers
沪公网安备 31010602006477号
a>